The Role of Bezlotoxumab for the Prevention of Recurrent Clostridioides difficile Infections: A Review of the Current Literature and Paradigm Shift after 2021

Clostridioides difficile infections (CDIs), and particularly recurrent infections, cause a significant burden on the health-care system. Bezlotoxumab is a new agent for the prevention of recurrent CDIs that has shown strong efficacy and high tolerability in clinical trials. The purpose of this revie...

Descripción completa

Detalles Bibliográficos
Autores principales: Hyte, Melanie L., Arphai, Lee J., Vaughn, Charles J., Durham, Spencer H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9495019/
https://www.ncbi.nlm.nih.gov/pubmed/36139989
http://dx.doi.org/10.3390/antibiotics11091211

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9495019/
https://www.ncbi.nlm.nih.gov/pubmed/36139989
http://dx.doi.org/10.3390/antibiotics11091211

Ejemplares similares